Retatrutide vs Tirzepatide vs Semaglutide: How the Triple Agonist Compares

The three compounds at a glance

All three are long-acting synthetic peptides engineered to mimic gut-derived incretin hormones. The differences are in which receptors each engages and how strongly.

• Semaglutide — a single-receptor GLP-1 agonist. Originally developed for type 2 diabetes (Ozempic) and later for chronic weight management (Wegovy).
• Tirzepatide — a dual GLP-1 / GIP receptor agonist (Mounjaro / Zepbound). Phase 3 SURMOUNT studies reported mean body weight reductions of up to 22.5% over 72 weeks.
• Retatrutide — a triple GLP-1 / GIP / glucagon receptor agonist. Phase 2 data published in the New England Journal of Medicine reported mean reductions of up to 24.2% over 48 weeks at the highest dose, with Phase 3 TRIUMPH readouts ongoing.

Receptor mechanism: why the third arm matters

GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide) are incretins released from the gut after eating. They potentiate insulin secretion, slow gastric emptying, and act centrally on appetite circuits. Tirzepatide demonstrated that simultaneously engaging both incretin receptors produces additive metabolic effects beyond GLP-1 alone.

The glucagon receptor occupies a different physiological role. Activation increases hepatic glucose output, but also raises basal energy expenditure and stimulates lipolysis. The translational hypothesis behind retatrutide is that pairing modest glucagon activity with strong GLP-1 / GIP agonism preserves the appetite and glycaemic benefits of incretin therapy while adding an energy-burning component on top.

Receptor profile summary

• Semaglutide: GLP-1R
• Tirzepatide: GLP-1R + GIPR
• Retatrutide: GLP-1R + GIPR + GCGR

What the published trial literature reports

The Phase 2 retatrutide obesity trial (Jastreboff et al., NEJM 2023) enrolled adults with a BMI ≥ 30 (or ≥ 27 with weight-related comorbidities) and reported dose-dependent body-weight reductions. At 48 weeks, the highest 12 mg dose produced a mean change of −24.2% compared with placebo, with secondary endpoints including improvements in waist circumference, blood pressure and lipid markers.

A separate Phase 2 metabolic-dysfunction-associated steatotic liver disease (MASLD) sub-study reported substantial reductions in liver fat content. Phase 3 TRIUMPH-1 through TRIUMPH-4 trials are evaluating efficacy and safety across obesity, type 2 diabetes, MASLD and cardiovascular outcomes, with results expected to read out through 2026 and 2027.

Tirzepatide's SURPASS (diabetes) and SURMOUNT (obesity) programmes remain the largest dataset on dual incretin agonism, and semaglutide's STEP and SUSTAIN trials anchor the GLP-1 single-agonist comparator. Cross-trial comparisons are indicative only — different populations, durations and titration schedules limit direct head-to-head conclusions until dedicated comparator studies report.

Reference-compound considerations for in-vitro research

For laboratory work, the questions that matter most are identity, purity and reproducibility. Reference material should be supported by independent HPLC purity verification, ideally from a recognised third-party laboratory, with a batch-specific Certificate of Analysis.

Sculpt Labs publishes every Janoshik Analytical batch report on our Purity Reports page. Our current retatrutide batch tests at 99% purity by HPLC. For reconstitution planning, the Sculpt Labs Reconstitution Calculator converts vial mass and diluent volume into mg/mL concentration for record-keeping.

Why retatrutide dominates 2026 discussion

Three factors have pushed retatrutide to the centre of peptide research conversation this year: the magnitude of the Phase 2 body-weight signal, the novelty of triple receptor engagement, and the volume of Phase 3 data expected through 2026. Independent researchers, clinicians and science writers continue to monitor the TRIUMPH programme closely, and reference-compound demand has risen alongside that interest.

Frequently asked questions